GeneOne Life Science, Inc.

KSE 011000.KS

GeneOne Life Science, Inc. Shares (Diluted, Weighted) for the year ending December 31, 2023: 77,749,896

GeneOne Life Science, Inc. Shares (Diluted, Weighted) is 77,749,896 for the year ending December 31, 2023, a 0.34% change year over year. Shares (diluted, weighted) are the number of outstanding shares used to calculate earnings per share (EPS) assuming the conversion of all potentially dilutive securities.

GeneOne Life Science, Inc. Shares (Diluted, Weighted) for the year ending December 31, 2022 was 77,485,718, a 4.37% change year over year.
GeneOne Life Science, Inc. Shares (Diluted, Weighted) for the year ending December 31, 2021 was 74,241,744, a 3.07% change year over year.
GeneOne Life Science, Inc. Shares (Diluted, Weighted) for the year ending December 31, 2020 was 72,029,676, a 100.59% change year over year.
GeneOne Life Science, Inc. Shares (Diluted, Weighted) for the year ending December 31, 2019 was 35,908,926, a -11.14% change year over year.

Key data

Date	Shares (Diluted, Weighted)	Revenue	Cost of Revenue	Gross Profit

KSE: 011000.KS

GeneOne Life Science, Inc.

CEO	Mr. Young-Keun Park J.D., M.B.A.
IPO Date	Feb. 4, 2000
Location	South Korea
Headquarters	The Pinnacle Gangnam
Employees	73
Sector	Health Care
Industries Biotechnology Clinical Trials Pharmaceuticals

Description

GeneOne Life Science, Inc., a biopharmaceutical company, engages in the development and contract manufacturing of gene-based-biomedicines. Its products comprise GLS-1027, which is in Phase I clinical trial for treatment of nephropathy and inflammatory diseases; GLS-1200 that is in Phase II clinical trial to treat Rhinosinusitis; GLS-1027 and GLS-1200, which is Phase II clinical trial for treatment of COVID-19. The company also develops GLS-3000 and GLS-5310 for the treatment of SARS-CoV-2; GLS-5100 to treat VZV-Shingles; and GLS-5140 for the treatment of SFTS. In addition, it is developing GLS-5300, which is in Phase II clinical trial for MERS; GLS-5700 that is in Phase I clinical trial for Zika; and GLS-6150, which is in Phase I clinical trial for treatment of hepatitis C, as well as GLS-6100 that is in pre-clinical stage for hepatitis C. Further, the company, through its subsidiary, VGXI, Inc., engages in the cGMP production of nucleic acid-based products, including DNA plasmids and mRNA. The company was formerly known as VGX International Inc. and changed its name to GeneOne Life Science, Inc. in April 2014. GeneOne Life Science, Inc. was founded in 1976 and is headquartered in Seoul, South Korea.

Key trends

Past 5 years